A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...
New evidence suggests that brief (4-session) motivational interviewing can reduce drug use and increase HIV prevention uptake ...
For decades scientists have recognized that human immunodeficiency virus (HIV) is a formidable viral pathogen.
A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...
From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. | From its ...
Brown researchers will look into how a drug originally developed to treat HIV may reduce age-related inflammation.
Union Health Ministry moves to remove repeated HIV, Hepatitis tests on pooled plasma to align with global norms and ease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results